Eli Lilly on Wednesday said its experimental combination regimen showed greater weight loss than a high dose of its top-selling drug, tirzepatide, alone in a mid-stage trial on patients with obesity and Type 2 diabetes. The combo therapy met the study's main goals in a population that typically struggles to lose weight. The results boost hopes that it could serve as an alternative blockbuster treatment option for people who didn't respond to or see the results they wanted on the current GLP-1 products on the market. Lilly said it plans to start Phase 3 trials on the regimen at the end of the year.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。